NYXH Nyxoah
Price Chart
Executive Summary
Nyxoah reported Q1 2026 EPS of $-0.37, beating consensus of $-0.44 (15.5% beat), while revenue of $7.6M was in line. The press release highlighted early US commercial momentum of the Genio system post-FDA approval. The EPS beat is positive but occurred on a small base, and no guidance was provided.
Actionable Insight
The EPS beat and US commercial ramp are positive signals, but with only one quarter of post-FDA data and no guidance, the trajectory is uncertain. Monitor next quarter for sustained revenue growth and cash burn.
Key Facts
- Q1 2026 EPS $-0.37 vs consensus $-0.44 (15.5% beat)
- Revenue $7.6M in line with consensus
- Press release emphasizes strong early US commercial progress for Genio system
- No guidance or forward-looking financial metrics provided
Financial Impact
EPS beat by $0.07 (15.5%) on consensus of -$0.44; revenue in line at $7.6M
Risk Factors
- Early-stage revenue base ($7.6M quarterly) makes growth comparisons volatile
- No guidance provided, limiting forward visibility
- Potential dilution risk given cash burn for commercial expansion
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298846 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
6-K
| $1.49 awaiting T+5 | awaiting T+5 | — | $1.39 (+6.40%) |
|
Jun 8, 2026
4d ago
|
6-K
| $1.36 awaiting T+5 | awaiting T+5 | — | $1.39 (−2.21%) |
|
Jun 8, 2026
5d ago
|
424B5
| $1.69 awaiting T+5 | awaiting T+5 | — | $1.39 (+17.75%) |
|
Jun 5, 2026
7d ago
|
Press Release
| $1.59 awaiting T+5 | awaiting T+5 | — | $1.39 (+12.58%) |
|
Jun 4, 2026
8d ago
|
424B5
| $1.73 awaiting T+5 | awaiting T+5 | — | $1.39 (+19.65%) |
|
May 20, 2026
23d ago
|
Press Release
| $2.87 $2.99 | ▲ +4.18% | ▲ +2.58% | $1.39 (−51.57%) |
|
May 12, 2026
4w ago
|
Press Release
| $3.08 $2.81 | ▼ −8.77% | ▼ −7.61% | $1.39 (−54.87%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $3.08 $2.82 | ▼ −8.44% | ▼ −6.29% | $1.39 (−54.87%) |
|
Mar 5, 2026
14w ago
|
Press Release
| $3.74 $3.14 | ▼ −16.04% | ▼ −14.51% | $1.39 (−62.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access